Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 160

Sort by

Sort Order Select

Journal Articles

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Blood (2024) 143 (18): 1807–1815.

https://doi.org/10.1182/blood.2023022725

Published: 2024

Includes: Supplemental data

Journal Articles

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Blood (2023) 142 (Supplement 1): 5429.

https://doi.org/10.1182/blood-2023-180970

Published: 2023

Journal Articles

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Blood (2023) 142 (Supplement 1): 5024.

https://doi.org/10.1182/blood-2023-180691

Published: 2023

Journal Articles

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Mireya Morote-Faubel, Maria Guaita-Céspedes, Beatriz Fernández-Blanco, Cristina Martínez-Valiente, Cristian García-Ruiz, Marta Santiago, Alvaro Diaz-Gonzalez, Alejandra Sanjuan-Pla, Mariam Ibáñez, Eva Barragan, Esperanza Such, Mireya Morote Faubel, Pau Montesinos, Javier De La Rubia, Alessandro Liquori, Jose Cervera

Blood (2023) 142 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2023-177571

Published: 2023

Journal Articles

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Blood (2023) 142 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2023-182876

Published: 2023

Journal Articles

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Blood (2023) 142 (Supplement 1): 3324.

https://doi.org/10.1182/blood-2023-184837

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Blood (2022) 140 (Supplement 1): 2098–2100.

https://doi.org/10.1182/blood-2022-165441

Published: 2022

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Blood (2022) 140 (Supplement 1): 4315–4317.

https://doi.org/10.1182/blood-2022-158538

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood (2022) 140 (Supplement 1): 7286–7288.

https://doi.org/10.1182/blood-2022-162584

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood (2021) 138 (19): 1901–1905.

https://doi.org/10.1182/blood.2021012319

Published: 2021

Includes: Supplemental data

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Blood (2021) 138 (Supplement 1): 544.

https://doi.org/10.1182/blood-2021-151557

Published: 2021

NARROW

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only